Thursday, January 21, 2010

Biocon Q3 cons net profit up 186.88% at Rs 80.9 cr

Biocon has declared its third quarter results of FY10. Its consolidated net profit increased 186.88% to Rs 80.9 crore versus Rs 28.2 crore, on year-on-year basis (YoY).

Consolidated net sales went up 45.6% to Rs 635.1 crore from Rs 436.2 crore (YoY). 9M FY10 EPS is at Rs 10.72. Operating profit margin (OPM) declined to 19.9% versus 21.8%.

The numbers were better-than-expectations. CNBC-TV18 was expecting revenues at Rs 557.9 crore, OPM at 20.5% and PAT at Rs 79.52 crore.

Highlights

-Adjusted PAT at Rs 80.89 crore versus Rs 74 crore
-Q3FY09 saw forex loss of Rs 45.8 crore
**Include results of Axicorp from July 1 2009 to Sept 30 2009
**Co concluded acquisition of API business if IDL Specialty Chemicals

Segment wise

-Revenue growth seen from the Pharma segment which increased 50% to Rs 565.7 crore versus Rs 375.4 crore.
-Contract Research also grew 21% to Rs 77.45 crore versus Rs 63.84 crore
-Margins decreased as total expenses increased 49% to Rs 508 crore
-Raw material costs increased 49.6% to Rs 355.6 crore
-Employee costs increased 29% to Rs 63.7 crore and other expenses were up 28% to Rs 73.7 crore
-PAT sustained as there are no forex losses this quarter
-On an APAT level the interest costs fall 25% to Rs 2.72 crore.
-And tax outflow increased to Rs 11.2 crore versus Rs 5.8 crore

Particulars Dec-09 Sep-09 Jun-09 Mar-09
Net Sales / Interest Earned / Operating Income 309.84 301.1 251.58 229.72
Other Income 6.14 11.34 7.13 10.12
Expenditure -223.16 -223.86 -184.21 -169.71
Interest -0.36 -0.26 -0.75 -0.9
Profit Before Depreciation and Tax 92.46 88.32 73.75 69.23
Depreciation -20.03 -19.8 -19.63 -19.25
Profit before Tax 72.43 68.52 54.12 49.98
Tax -6.63 -6.16 -6.57 2.04
Profit after Tax 65.8 62.36 47.55 52.02
Extraordinary Items - - - -27.88
Net Profit 65.8 62.36 47.55 24.14
Equity Capital 100 100 100 100

























No comments:

Post a Comment